Jill Feldman: EQUAL Study Spotlight
Jill Feldman, Lung Cancer Patient and Advocate, and Co-Founder of EGFR Resisters, shared a post on X by Florez Lab, adding:
“Anyone can get lung cancer and EVERYONE at risk deserves access to screening, treatment and quality care.
The EQUAL Study is working to make early lung cancer detection more equitable using an innovative blood test designed to detect EGFR NSCLC.
It focuses on people in Hispanic and East Asian communities who do not have a history of tobacco use – a population that may be at risk but historically overlooked.”
Quoting Florez Lab‘s post:
“EQUAL SPOTLIGHT
After losing multiple family members to lung cancer and being diagnosed at 39, Jill Feldman searched for answers and a community.
She helped build EGFR Resisters and now fights for equity in lung cancer screening.”
Watch the video attached to this post.
More posts featuring Jill Feldman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023